What is the long-term trend for Janux Therapeutics's contract liabilities, non-current?

Over 4 years (2020 to 2025), Janux Therapeutics's contract liabilities, non-current has grown at a -100.0% compound annual growth rate (CAGR), from $6.05M to $0.

Janux Therapeutics JANX Contract Liabilities, Non-Current

Contract Liabilities, Non-Current at other companies

Regeneron PharmaceuticalsREGN

——

Arcus BiosciencesRCUS

——

Other financials

Income statement

See full

Revenue$3.7M—

Operating income-$34.2M+2.0%

Net income-$24.4M-3.6%

EPS (diluted)-$0.39-2.6%

Balance sheet

See full

Cash & equivalents$51.8M-29.7%

Total debt$21.6M-4.6%

Total equity$941.5M-7.0%

Total assets$1.0B-2.1%

Cash flow

See full

Operating cash flow-$12.3M+27.5%

CapEx$273.0K-26.4%

Free cash flow-$12.6M+27.5%

Valuation

See full

Market cap$889.15M-36.3%

Enterprise value$858.89M-36.2%

P/S64.8×-84.8×

Profitability

See full

Operating margin-1,143.1%-65.1pp

Net margin-833.6%+0.9pp

FCF margin-571.6%+98.3pp

Returns & leverage

See full

Return on equity-11.7%+4.1pp

Debt / equity0×0.0×

Current ratio17×-41.5×

Where this comes from

Reported directly by Janux Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityNoncurrent.

The official record: Janux Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Janux Therapeutics's contract liabilities, non-current.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Janux Therapeutics's contract liabilities, non-current?: Janux Therapeutics (JANX) reported contract liabilities, non-current of $8.68M in Q1 2026.
What is the long-term trend for Janux Therapeutics's contract liabilities, non-current?: Over 4 years (2020 to 2025), Janux Therapeutics's contract liabilities, non-current has grown at a -100.0% compound annual growth rate (CAGR), from $6.05M to $0.